Each of the four Cancer Immune Monitoring and Analysis Centers (CIMACs) provides genomic, phenotypic, and functional analyses for correlative studies in clinical trials involving cancer immunotherapy. Deep molecular characterization of tumor and immune profiling is achieved using state-of-the-art, analytically validated, and standardized platforms. Multi-disciplinary teams within each CIMAC contribute specialized experimental and analytical expertise to advance translational research efforts.

The CIMACs are:

Dana-Farber Cancer Institute

Icahn School of Medicine at Mount Sinai

MD Anderson Cancer Center

Stanford University

The CIDC provides a bioinformatics platform for integrative analysis of biomarker and clinical data across studies. The CIMACs work collaboratively with the CIDC to enable data standardization and develop uniform analysis pipelines across the network’s studies. CIMAC-CIDC Network investigators and clinical trial investigators work together on correlative analyses correlating biomarker data from biospecimens from cancer immunotherapy trials with clinical data from those trials.